Pulmatrix Inc (PULM) Stock Price, Quote & News

Company Profile

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clin...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 355 4440

Website: www.pulmatrix.com

Address:

945 Concord Street, Suite 1217, Framingham, United States

Nakom Dec. 4 at 7:28 PM

$PULM I can feel it coming in the air tonight oh lord. Well I’ve been waiting for this moment for all my life, oh lord. Super bullish

0 · Reply

Nakom Dec. 4 at 4:45 PM

$PULM Huge volume today. Not. Everyone must be anticipating. Wait for it. Wait for it. MERGER MONNNDDDAAAYYY!!! Super bullish

0 · Reply

Nakom Dec. 4 at 2:07 PM

$PULM one share purchased premarket. Wow 🤩

1 · Reply

Love_To_Learn Dec. 3 at 7:27 PM

$CAPR will use your old trigger long wedge 16-19 pt for markets and the 38-42 buyout ofer commencing which has been shifted from $PULM vault and database

1 · Reply

Love_To_Learn Dec. 3 at 7:19 PM

$DEVS addressing batman robin dynamic $SLS also coding $PULM buyout for market transfer buyout using pulm

2 · Reply

Nakom Dec. 3 at 4:47 PM

$PULM Could this coming Monday finally be merger Monday. Could be. Especially if Cullgen wants to participate at the upcoming JP Morgan conference.

0 · Reply

hippo_hungry Dec. 3 at 3:56 PM

$PULM chart is holding on by thread.. if no news … oof.. back to $2

1 · Reply

Nakom Dec. 1 at 4:03 PM

$PULM ONLY 4 MORE MERGER MONDAYS LEFT!!!

0 · Reply

Nakom Nov. 29 at 12:25 PM

$PULM There are only five more MERGER MONDAYS left in the year. I have to be right one of these MONDAYS!!!

1 · Reply

Nakom Nov. 28 at 6:11 PM

$PULM Meger Monday?????

1 · Reply

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Aug 6, 2025, 9:58 PM EDT - 4 months ago

Pulmatrix (PULM) Q2 Revenue Falls 100%

Aug 6, 2025, 8:05 AM EDT - 4 months ago

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

May 15, 2025, 8:05 AM EDT - 7 months ago

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 9, 2025, 4:00 PM EDT - 7 months ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Mar 21, 2025, 8:05 AM EDT - 9 months ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Nov 15, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

Nov 13, 2024, 9:00 AM EST - 1 year ago

Pulmatrix and Cullgen Announce Proposed Merger

Nov 8, 2024, 10:26 AM EST - 1 year ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 8:45 AM EDT - 1 year ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MNKD

May 15, 2024, 9:35 AM EDT - 1 year ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 10, 2024, 8:05 AM EDT - 1 year ago

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

Mar 28, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Jan 8, 2024, 9:00 AM EST - 2 years ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Nov 9, 2023, 9:05 AM EST - 2 years ago

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 19, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Aug 23, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Aug 10, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 11, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Jun 15, 2023, 9:20 AM EDT - 2 years ago

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

May 24, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 12, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 2, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Supports World Asthma Day 2023

Mar 30, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Feb 6, 2023, 9:10 AM EST - 3 years ago

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Jan 25, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Jan 23, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Jan 4, 2023, 9:05 AM EST - 3 years ago

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Nov 10, 2022, 9:05 AM EST - 3 years ago

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 26, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Aug 8, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 12, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

May 12, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Mar 29, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Mar 21, 2022, 12:45 PM EDT - 4 years ago

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Mar 21, 2022, 8:05 AM EDT - 4 years ago

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Mar 17, 2022, 4:05 PM EDT - 4 years ago

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Mar 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Feb 24, 2022, 4:05 PM EST - 4 years ago

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Feb 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Issues Letter to Stockholders

Dec 17, 2021, 4:30 PM EST - 4 years ago

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Dec 15, 2021, 8:00 AM EST - 4 years ago

Pulmatrix Announces $6.75 Million Registered Direct Offering

Nov 10, 2021, 4:15 PM EST - 4 years ago

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 9, 2021, 9:00 AM EST - 4 years ago

Pulmatrix Announces Resolution of Contract Dispute with Cipla

Aug 10, 2021, 9:10 AM EDT - 4 years ago

Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update

Jul 27, 2021, 10:00 AM EDT - 4 years ago

Pulmatrix appoints Director Anand Varadan

Nakom Dec. 4 at 7:28 PM

$PULM I can feel it coming in the air tonight oh lord. Well I’ve been waiting for this moment for all my life, oh lord. Super bullish

0 · Reply

Nakom Dec. 4 at 4:45 PM

$PULM Huge volume today. Not. Everyone must be anticipating. Wait for it. Wait for it. MERGER MONNNDDDAAAYYY!!! Super bullish

0 · Reply

Nakom Dec. 4 at 2:07 PM

$PULM one share purchased premarket. Wow 🤩

1 · Reply

Love_To_Learn Dec. 3 at 7:27 PM

$CAPR will use your old trigger long wedge 16-19 pt for markets and the 38-42 buyout ofer commencing which has been shifted from $PULM vault and database

1 · Reply

Love_To_Learn Dec. 3 at 7:19 PM

$DEVS addressing batman robin dynamic $SLS also coding $PULM buyout for market transfer buyout using pulm

2 · Reply

Nakom Dec. 3 at 4:47 PM

$PULM Could this coming Monday finally be merger Monday. Could be. Especially if Cullgen wants to participate at the upcoming JP Morgan conference.

0 · Reply

hippo_hungry Dec. 3 at 3:56 PM

$PULM chart is holding on by thread.. if no news … oof.. back to $2

1 · Reply

Nakom Dec. 1 at 4:03 PM

$PULM ONLY 4 MORE MERGER MONDAYS LEFT!!!

0 · Reply

Nakom Nov. 29 at 12:25 PM

$PULM There are only five more MERGER MONDAYS left in the year. I have to be right one of these MONDAYS!!!

1 · Reply

Nakom Nov. 28 at 6:11 PM

$PULM Meger Monday?????

1 · Reply

Lift_Like_Gaston Nov. 28 at 5:28 AM

$PULM happy Thanksgiving sit tight folks this bitch is gonna go nuclear ☢️ 🤯

0 · Reply

Kastila Nov. 27 at 10:54 PM

$PULM What will happen to the stock if merger does not happen this year? There is a month left. The company says that it would be this year @Nakom What's your thought on this?

1 · Reply

Love_To_Learn Nov. 26 at 8:37 PM

$PULM BRINGING U COMPANY AND FRIENDS FROM BOTTOM !

1 · Reply

Nakom Nov. 26 at 7:54 PM

$PULM some crazy movement in the stock today. Is it because we are getting closer to MERGER MONDAY. Will December be the month to remember. Stay tuned people. HAPPY THANKSGIVING EVERYONE!!!

0 · Reply

anatoma1 Nov. 25 at 9:05 PM

$PULM Any nice paint job! It doesn’t even matter anymore, the price will be the price.

1 · Reply

Yssie Nov. 25 at 4:31 PM

$PULM is this cooked ? pretty bad sign there is no update on merger makes me think it wont happen.

2 · Reply

Love_To_Learn Nov. 25 at 12:53 PM

$BDRX indirectly communicating also with $PULM this is in regards to a buyout offer coming for another stock of $38-41.5 a share later for market

5 · Reply

Nakom Nov. 24 at 4:56 PM

$PULM I’m calling this coming week MERGER THANKSGIVING HOLIDAY!!! You got that right. Pulmatrix/Cullgen will merger over the using Holiday. So hold on tight it Will be an unbelievable ride.

0 · Reply

Nakom Nov. 24 at 2:55 PM

$PULM Picked up another 65 shares at $4.50. Have a happy thank fellow longs.

0 · Reply

anatoma1 Nov. 23 at 12:10 AM

$PULM They will say something when they have something to say. Waiting on Culgen’s CSRC approval. Approval delayed bcos of US/China tariff issues which is now over.

0 · Reply

arrosto Nov. 22 at 1:26 PM

$PULM Shouldn't the company have to say something? I know that no-one actually works there but still. Less than one month till year end getting ridiculous.

1 · Reply

Nakom Nov. 21 at 8:22 PM

$PULM It’s just another manic merger Monday!!!

0 · Reply

Market Cap	16.17M
Revenue (ttm)	7.81M
Net Income (ttm)	-9.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-122.41%
Debt to Equity Ratio	0.00

Volume	5,500
Avg Vol	10,638
Day's Range	N/A - N/A
Shares Out	3.65M
Stochastic %K	2%
Beta	1.58
Analysts	Strong Buy
Price Target	$10.00